Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Recommendation of “Buy” from Brokerages

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) have been given a consensus recommendation of “Buy” by the nine brokerages that are currently covering the company, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have covered the stock in the last year is $18.33.

Several analysts have recently weighed in on INZY shares. Raymond James started coverage on shares of Inozyme Pharma in a research note on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Wedbush reiterated an “outperform” rating and issued a $12.00 price objective on shares of Inozyme Pharma in a research note on Friday, January 10th. Wells Fargo & Company lowered their price objective on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Finally, HC Wainwright boosted their price target on shares of Inozyme Pharma from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

Institutional Trading of Inozyme Pharma

Several institutional investors have recently made changes to their positions in INZY. Affinity Asset Advisors LLC grew its stake in shares of Inozyme Pharma by 40.7% in the 4th quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company’s stock worth $11,003,000 after acquiring an additional 1,150,000 shares in the last quarter. Sanofi bought a new stake in shares of Inozyme Pharma in the 4th quarter worth $1,228,000. Renaissance Technologies LLC grew its stake in shares of Inozyme Pharma by 155.7% in the 4th quarter. Renaissance Technologies LLC now owns 421,399 shares of the company’s stock worth $1,167,000 after acquiring an additional 256,599 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Inozyme Pharma in the 4th quarter worth $658,000. Finally, Eventide Asset Management LLC grew its stake in shares of Inozyme Pharma by 5.0% in the 3rd quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock worth $21,623,000 after acquiring an additional 198,216 shares in the last quarter. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Stock Performance

NASDAQ:INZY opened at $1.19 on Friday. The company has a fifty day moving average of $1.73 and a 200-day moving average of $3.44. The firm has a market capitalization of $76.45 million, a P/E ratio of -0.76 and a beta of 1.32. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a twelve month low of $1.04 and a twelve month high of $7.80.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.